Novo Nordisk(US:NVO) Cai Jing Wang·2026-02-09 08:28Core Insights - Novo Nordisk announced the official launch of injectable pegylated recombinant factor VIII (brand name: Nuwiq®) in mainland China, marking it as the only long-acting recombinant factor VIII approved in the country [1] - Nuwiq® has been added to the new national medical insurance catalog, enhancing accessibility for patients with Hemophilia A and ushering them into a new treatment phase [1] Group 1: Product and Market Impact - Nuwiq® fills a significant gap in long-term treatment for Hemophilia A in China, which affects approximately 80%-85% of all hemophilia patients [1] - The product's launch is expected to improve medication accessibility for patients, who require lifelong treatment to avoid severe health risks [1] Group 2: Clinical Data and Efficacy - Since its approval in the U.S. in 2019, Nuwiq® has accumulated extensive efficacy and safety data for the prevention and treatment of bleeding globally [1] - In a multi-center trial (Pathfinder10) conducted among Chinese Hemophilia A patients, the median annualized bleeding rate (ABR) for those receiving preventive treatment with Nuwiq® was 0.00, with 69.4% of patients experiencing zero bleeding events and a 94.8% success rate in stopping bleeding [1]